

Aims


Marlborough Far East Growth is a cell of Marlborough International Fund PCC Limited, a Class B collective investment scheme authorised by the Guernsey Financial Services Commission. The investment objective of the Cell is to provide long term capital growth by acting as a feeder fund into the Marlborough Far East Growth Cell, an actively managed UCITS fund authorised by the Financial Conduct Authority. All portfolio and performance data relates to the master fund.

Philosophy

The fund integrates fundamental company analysis within a thematic framework that seeks to identify areas with strong growth potential.

Performance - Master Fund, GBP

All performance data relates to GBP shares. USD and EUR share classes are unhedged.



	1 year	3 years	5 Years	Since Launch (22/11/2005)
Master Fund GBP	-13.6%	9.3%	3.4%	202.7%
IA Asia ex Japan Sector average	-4.5%	21.5%	27.5%	339.4%

All performance data as at 31/08/2022. Source: Morningstar, mid-mid, GBP, Net Inc reinvested.

To view additional portfolio information visit:

<http://funds.marlboroughfunds.com/doc/B0NVC69/factsheet.pdf>

ELITE PROVIDER

rated for equities by FundCalibre.com
2022



Process

The fund uses an integrated top-down and bottom-up process with a thematic overlay.

The thematic overlay seeks to identify factors which may influence markets, with themes broadly categorised as:

- Likely to occur in the next 12-18 months
- Multi-country, multi-year themes
- Single country themes.

Each theme identifies sectors and stocks likely to be impacted and estimates a likely time horizon. They sit in the background as signposts to note or follow, rather than prescriptive channels into which all stocks must fit.

Investment Advisers

The fund is managed by Szu Fuei Chong. Szu has more than 15 years' investment experience. She joined Hong Kong's BEA Union Investment Management as an investment analyst in 2011 and previously held roles with BNP Paribas Investment Partners and CLSA. Prior to that she was with Bank Negara Malaysia and the Malaysian Institute of Economic Research. Szu holds a BSc (Hons) in economics from the University of Hull and an MA in development economics from the University of East Anglia.

Key Points

- Integrated investment process uses a combination desk-based research and company management meetings
- Actively managed fund targets relatively high EPS and yield
- Highly experienced manager.

Contingent Deferred Charge:

5.0%

Total Expense Ratio (TER):

3.11%

Identification Codes:

GBP Sedol: BYY1Q75, ISIN: GG00BYY1Q756

(F Class shares)

EUR (unhedged) Sedol: BYY1QF3, ISIN: GG00BYY1QF33

USD (unhedged) Sedol: BYY1Q97, ISIN: GG00BYY1Q970

Manager Details:

Marlborough International Management Limited, PO Box 146, Level 2, Park Place, Park Street, St. Peter Port, Guernsey, GY1 3HZ

Administrator:

EPEA Fund Services (Guernsey) Limited, Suites 7 & 8, Fourth Floor, Windsor House, Le Pollet, St Peter Port, Guernsey, GY1 1WF

This information is for Financial Advisers only and should not be relied upon by Retail Investors. The past is not necessarily a guide to future performance. Investments and the income derived from them can fall as well as rise and the investor may not get back the amount originally invested. Data as at 01/09/2022.

Top 10 Holdings 01/09/2022

Name	% Weight
Taiwan Semiconductor Manufacturing	5.6
Samsung Electronics	5.0
Reliance Industries	4.1
Alibaba Group	3.4
Santos	3.3
United Overseas Bank	3.0
DBS Group	2.9
JD	2.7
SITC International	2.5
Kweichow Moutai	2.4

Monthly Fund Commentary

To view the master fund commentary [click here](#) or visit www.marlboroughfunds.com

This information is for Financial Advisers only and should not be relied upon by Retail Investors. The Far East Growth Cell referred to is a cell of Marlborough International PCC Limited (the 'Company'), a protected cell company incorporated in Guernsey and authorised as a Class B Collective Investment Scheme under the terms of the Protection of Investors (Bailiwick of Guernsey) law, 1987, as amended. Investment may only be made on the basis of the current Prospectus. The following is a summary only of some key items in the Prospectus. Investors in Protected Cell Company (PCC) must have the financial expertise and willingness to accept the risks inherent in this investment. These risks include inter alia, the fact that neither the past performance nor operating history of the Company is a guarantee of future performance. It should be appreciated that the value of Shares is not guaranteed and may go down as well as up and that investors may not receive, on redemption of their Shares, the amount that they originally invested. Investors should consult their professional advisers about the consequences to them, and inform themselves of the legal requirements for, acquiring, holding, exchanging redeeming or disposing of Shares under the relevant laws of the jurisdictions to which they are subject, including any tax consequences, exchange control requirements, requisite governmental or other consents and any other formalities. If you are in any doubt about the action you should take, you should consult a suitably qualified and licensed or authorised professional adviser who specialises in advising on the acquisition of shares and other securities. Investment in the Company should only be undertaken as part of a diversified investment portfolio. Investment in the Shares should be viewed as a medium term investment. Shares may not be redeemed otherwise than on any Dealing Day. The Shares of the Company are not listed on any stock exchange and it is not anticipated that there will be any secondary market in the Shares. Changes in exchange rates may cause the value of the fund to rise or fall. The Fund invests in less developed overseas markets which may be less liquid and more volatile than more developed markets. The Fund has a concentrated portfolio which means greater exposure to a smaller number of securities than a more diversified portfolio. Data accurate as of 01/09/2022.